Evoke Pharma Inc (: EVOK)

Evoke Pharma Inc, also known as EVOK, is a specialty pharmaceutical company that operates within the healthcare industry, specifically focusing on developing and commercializing drugs to treat gastrointestinal (GI) disorders and diseases. The company's primary product, Gimoti, is a nasal spray formulation of metoclopramide, the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

In terms of its main business activities, Evoke Pharma is dedicated to developing and bringing to market products that address significant unmet medical needs in the GI market. The company's primary objective is to commercialize Gimoti in the United States and expand its market potential by developing a lower dosage strength of the product. Additionally, Evoke Pharma is seeking partnerships to accelerate and maximize the potential of Gimoti, as well as in-licensing or acquiring additional clinical or commercial-stage product candidates for the treatment of GI diseases.

Evoke Pharma generates revenue through the sales of Gimoti. This product is a nasal spray formulation of metoclopramide, a dopamine receptor antagonist that is designed to bypass the digestive system, providing predictable absorption without the need to determine if a patient's stomach is functioning. This is particularly beneficial for patients with gastroparesis, who often experience erratic or delayed gastric emptying, making it difficult to absorb oral medications. The nasal spray formulation of metoclopramide offers an alternative route of administration for patients with severe symptoms of diabetic gastroparesis, including those who experience nausea and vomiting.

The market for gastroparesis treatment is currently served by oral metoclopramide, intravenous metoclopramide, and the oral disintegrating tablet (ODT) formulation of metoclopramide. However, these products have limitations, including erratic absorption and potential side effects. Gimoti, with its nasal spray formulation, offers a novel and convenient alternative for patients with gastroparesis.

Evoke Pharma's competitive position within the industry is strong, with a unique product that addresses a significant unmet medical need. The company's partnership with Eversana provides a strong commercial infrastructure, and its focus on developing a lower dosage strength of Gimoti will help to expand its market potential. Additionally, Evoke Pharma's intellectual property portfolio, which includes patents and patent applications, provides protection for its technology and products.

Evoke Pharma's customers include healthcare professionals, such as gastroenterologists and primary care physicians, as well as patients with gastroparesis. The company's marketing strategy focuses on educating these healthcare professionals about the benefits of Gimoti and promoting the product through social media and digital channels.